- Alterola Biotech Inc. acquires ABTI Pharma Ltd as part of its strategic move into the cannabinoid medicines sector.
Liverpool, UK, 22 July 2021, ZEXPRWIRE, Alterola Biotech Inc. (OTC: ABTI), today announces the acquisition of ABTI Pharma Ltd, a company developing novel cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical medicines, active pharmaceutical ingredients (APIs) and other ingredients.
The acquisition of ABTI Pharma Ltd follows Alterola’s recent change of strategic direction into the cannabinoid medicines sector, and has resulted in a new management team for the Company.
As part of the acquisition of ABTI Pharma Ltd, the Company now has a number of potential drug development candidates, technologies and associated intellectual property in its portfolio, which will form part of the Company’s research and development (R&D) pipeline. This includes potential drug candidates for the treatment of a number of indications, and access to drug delivery technologies, which it believes will be beneficial to the Company’s development pipeline. The Company plans to undertake the necessary R & D to progress these candidates through the usual regulatory pharmaceutical drug development process.
Alterola’s CEO, Mr. Seamus McAuley, said:
“I am delighted that Alterola has now completed the acquisition of ABTI Pharma Ltd. The acquisition reaffirms the Company’s intention to develop pharmaceutical medicines with therapeutic potential, which contain cannabinoid and cannabinoid-like molecules.”
Details of Alterola’s Executive Staff:
Mr. Tim Rogers (Executive Chairman) Mr. Rogers has lived and worked extensively across the globe for over 30 years. Tim has an accountancy background, is multi-lingual, with global experience in start-ups from Singapore, SE Asia, Australia, USA, Canada and Europe. He has significant experience in pharmaceuticals, agriculture, essential oils & cosmetics sectors and has strong European relationships with distributors.
Mr. Seamus McAuley (CEO)
Mr. McAuley is a specialist in the commercial strategy, launch and growth of med-tech products and his experience spans a wide variety of sectors and therapeutic markets. A specialist in mergers and acquisitions, he brings a strong analytical, stakeholder management and leadership skills to proactively deliver new opportunities. A highly strategic leader, with an innate focus on innovation and future capability, Seamus demonstrates a proven capacity and successful results across the commercial environment through strong and focused leadership.
Colin Stott (Chief Operations Officer)
Colin Stott brings over 30 years’ experience in preclinical and clinical pharmaceutical development, with specific expertise in the development of botanical medicines, including cannabinoid / cannabis-based medicines. Most notably, from 2001, he spent more than 16 years as Director of Research and Development operations for GW Pharma, where he was directly involved in the development, approval and launch of Epidiolex® and Sativex®. During his time at GW, he also managed GW’s discovery and development pipeline and is a named inventor on many of their key patents. From 2017-2019, he was Scientific Affairs Director for GW Pharma for their International Division, and was part of the Medical Affairs team responsible for the preparation of the international (ex-US) launch of Epidiolex®.
Prior to his 19-year tenure at GW Pharmaceuticals, Mr. Stott held various roles in clinical research and development across a range of therapeutic areas, including: cardiology, oncology, urology, dermatology, metabolic disorders, neurology, haematology, and organ transplantation. He has published over 20 research papers and is a named inventor on 19 international patent applications.
Dominic Schiller (Chief Intellectual Property Officer)
Mr. Schiller is a qualified European Patent Attorney, and a specialist in intellectual property law within the cannabinoid pharmaceutical sector. He specializes in building patent portfolios for biotech companies. Most notably, he helped create and secure some of the earliest and most prominent cannabinoid related patents for GW Pharma, helping them establish an IP portfolio comprising claims directed to plants, plant extracts, extraction technology, pharmaceutical formulations, drug delivery and the therapeutic uses of cannabinoids, as well as plant variety rights. He has also served as patent attorney for a number of other pharma / biotech companies, securing patents relating to variety of botanically-derived and synthesized medicines, formulations and their medical use.. Mr. Schiller serves as IP Counsel to the Company.
About Alterola Biotech Inc.
ALTEROLA BIOTECH INC. (OTC: “ABTI”) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary product platform across a broad range of therapeutic areas. The Company has a number of proprietary drug pipeline candidates including cannabinoids, cannabinoid-like molecules and non-cannabinoid molecules, which are under development for a range of indications. ABTI is also focussed on producing quality, low cost of goods ingredients for the pharmaceutical, food and cosmetic sectors, from synthetic, biosynthetic and botanical sources. It is also focussed on improving the drug delivery of such classes of compounds and has a range of proprietary technologies in development to enhance the delivery and bioavailability of its product portfolio. Geographically the Company has a presence in the UK, Ireland, Netherlands (Europe), USA, Australia, and China.
If you would like more information about this topic, please call Investor Relations at +44 (0) 7547 560152, or email email@example.com
47 Hamilton Square, Birkenhead, Merseyside, CH41 5AR, UK.
Tel: +44 (0) 151 601 9477
Legal Notice Regarding Forward-Looking Statements in this news release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined, and assumptions of management. Forward-looking statements are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Actual results may differ materially from those currently anticipated due to a number of factors beyond the reasonable control of the Company. It is important to note that actual outcomes and the Company’s actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include misinterpretation of data, the Company’s ability to raise financing for operations, breach by parties with whom we have contracted, and the possible inability to maintain qualified employees or consultants.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Sahyadri Times journalist was involved in the writing and production of this article.